Effect of entecavir combined with TACE on the quality of life, liver function and immune function of patients with primary liver cancer
10.3760/cma.j.issn.1008-6706.2020.18.010
- VernacularTitle:恩替卡韦辅助治疗经肝动脉化疗栓塞术后原发性肝癌疗效观察及对患者生存质量、肝功能和免疫功能影响
- Author:
Jiaping WANG
1
;
Xiaochun TENG
Author Information
1. 浙江省，嘉兴市第二医院药学部 314000
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(18):2215-2219
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of entecavir combined with transcatheter arterial chemoembolization (TACE) on the quality of life, liver function and immune function of patients with primary liver cancer.Methods:From January 2017 to December 2018, 120 patients with primary liver cancer admitted to the Second Hospital of Jiaxing were randomly divided into observation group(60 cases) and control group(60 cases). The patients in the control group were treated with TACE, while those in the observation group were treated with entecavir on the basis of the control group.Both two groups were treated for 3 consecutive courses, and 4 weeks as a course of treatment.The short-term effect, KPS score, liver function and immune function of the two groups were compared before and after treatment.Results:The total effective rate of the observation group(71.67%) was higher than that of the control group(50.00%)(χ 2=5.911, P<0.05). The KPS score of the observation group was (84.25±3.67)points, which was higher than that of the control group[(75.58±3.29)points]( t=13.626, P<0.05). After treatment, the levels of ALT [(35.42±6.24)U/L], TBIL [(23.37±2.89)μmol/L] and AST [(37.29±4.23)U/L] in the observation group were lower than those in the control group [(52.29±4.56)U/L, (30.73±3.78)μmol/L and (54.35±3.89)U/L]( t=16.908, 11.982, 22.995, all P<0.05). The CD 3+ [(58.71±2.93)%], CD 4+ /CD 3+ [(39.74±3.45)%] and CD 4+ /CD 8+ (1.65±0.39) in the observation group were higher than those in the control group [(49.63±3.10)%, (31.12±2.13)% and (0.93±0.17)] ( t=16.489, 16.468, 13.109, all P<0.05). Conclusion:Entecavir combined with TACE is effective in the treatment of primary liver cancer, and it can improve the quality of life, liver function and immune function.
